The first domestically produced children’s anti- influenza productNew drug marketing application accepted
September 6, 2025
Source: drugdu
92
On September 3, the marketing application for Madeuroxavir Granules, developed jointly by Simcere Pharmaceuticals and Antikang Biopharmaceuticals, was accepted for use in the treatment of uncomplicated influenza A and B in children aged 2 to 11 years. This is the first innovative anti -influenza virus drug for pediatric patients in China to successfully complete Phase III clinical trials and be approved for marketing..
Comment: If approved, the first domestically produced pediatric anti-influenza drug will create a new growth point for Simcere Pharmaceuticals and enhance its competitiveness in the anti-influenza market. It also demonstrates Antikang Biopharmaceuticals' strength in innovative drug research and development, helping to boost its valuation in the capital market.
https://finance.eastmoney.com/a/202509053505290366.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
